Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

Autor: Hájek, R. Minarík, J. Straub, J. Pour, L. Jungova, A. Berdeja, J.G. Boccadoro, M. Brozova, L. Spencer, A. Van Rhee, F. Vela-Ojeda, J. Thompson, M.A. Abonour, R. Chari, A. Cook, G. Costello, C.L. Davies, F.E. Hungria, V.T.M. Lee, H.C. Leleu, X. Puig, N. Rifkin, R.M. Terpos, E. Usmani, S.Z. Weisel, K.C. Zonder, J.A. Barinová, M. Kuhn, M. Šilar, J. Cápková, L. Galvez, K. Lu, J. Elliott, J. Stull, D.M. Ren, K. Maisnar, V.

Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::51960a425cfb7119a2d896c0a8be5568
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077072

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.

Autor: Hájek R; University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic., Minařík J; Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic., Straub J; General Teaching Hospital, Prague, 128 08, Czech Republic., Pour L; University Hospital, Brno, 625 00, Czech Republic., Jungova A; Faculty Hospital Pilsen, Pilsen, 301 00, Czech Republic., Berdeja JG; Sarah Cannon Research Institute, Nashville, TN 37203, USA., Boccadoro M; University of Torino, Torino, 10124, Italy., Brozova L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Spencer A; Alfred Health-Monash University, Melbourne, 3004, Australia., van Rhee F; University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Vela-Ojeda J; UMAE Especialidades Centro Medico La Raza IMSS, Ciudad de México, 02990, Mexico., Thompson MA; Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI 53227, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Cook G; Leeds Teaching Hospital, Leeds, LS1 3EX, UK., Costello CL; Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Davies FE; Perlmutter Cancer Center, NYU Langone, New York, NY 10016, USA., Hungria VT; Clinica São Germano & Santa Casa Medical School, São Paulo, 04537-081, Brazil., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Leleu X; Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, 86000, France., Puig N; Department of Hematology, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16/12/00233), Salamanca, 37007, Spain., Rifkin RM; Rocky Mountain Cancer Centers US Oncology Research, Denver, CO 80218, USA., Terpos E; National & Kapodistrian University of Athens, School of Medicine, Athens, 115 27, Greece., Usmani SZ; Levine Cancer Institute, Charlotte, NC 115 27, USA., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany., Zonder JA; Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI 48201, USA., Bařinová M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Kuhn M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Šilar J; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Čápková L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Galvez K; Hospital Pablo Tobón Uribe, Medellin, 11001, Colombia., Lu J; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing, 100044, China., Elliott J; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Stull DM; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Ren K; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Maisnar V; Charles University Hospital & Faculty of Medicine, Hradec Králové, 121 08, Czech Republic.

Publikováno v: Future oncology (London, England) [Future Oncol] 2021 Jul; Vol. 17 (19), pp. 2499-2512. Date of Electronic Publication: 2021 Mar 26.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Testing Computer Models Predicting Human Responses to a High-Salt Diet.

Autor: Kurtz TW; From the Department of Laboratory Medicine (T.W.K.), School of Medicine, University of California, San Francisco., DiCarlo SE; Department of Physiology, College of Osteopathic Medicine, Michigan State University, East Lansing (S.E.D.)., Pravenec M; Institute of Physiology of the Czech Academy of Sciences, Prague (M.P.)., Ježek F; Department of Cybernetics, Czech Technical University in Prague (F.J.).; Department of Pathophysiology, 1st Faculty of Medicine, Charles University, Prague (F.J., J.S., J.K.)., Šilar J; Department of Pathophysiology, 1st Faculty of Medicine, Charles University, Prague (F.J., J.S., J.K.)., Kofránek J; Department of Pathophysiology, 1st Faculty of Medicine, Charles University, Prague (F.J., J.S., J.K.)., Morris RC Jr; Department of Medicine (R.C.M.), School of Medicine, University of California, San Francisco.

Publikováno v: Hypertension (Dallas, Tex. : 1979) [Hypertension] 2018 Dec; Vol. 72 (6), pp. 1407-1416.